Meeting
2017 ASCO Annual Meeting
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
Authors
Ines Maria Vaz Duarte Luis
Dana-Farber Cancer Institute, Boston, MA
Ines Maria Vaz Duarte Luis , Hao Guo , William Thomas Barry , Ian E. Krop , Nikhil Wagle , Alarice Lowe , Danielle Gore , Chelsea Andrews , Wafa Osmani , Steven J. Isakoff , Nadine M. Tung , Eric P. Winer , Nancy U. Lin , Rachel A. Freedman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT01912963
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1034)
DOI
10.1200/JCO.2017.35.15_suppl.1034
Abstract #
1034
Poster Bd #
26
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.
First Author: Rachel A. Freedman
First Author: Nicholas Patrick McAndrew
Poster
2014 ASCO Annual Meeting
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
First Author: Shannon Puhalla
Poster
2013 ASCO Annual Meeting
Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer.
First Author: Helen K. Chew